Prozac Tapering Guide
fluoxetine
Boxed Warning
Suicidality risk in children, adolescents, and young adults under 25 during initial treatment.
Overview
Fluoxetine was the first SSRI approved in the US and remains one of the most widely prescribed antidepressants. It is approved for major depressive disorder, OCD, panic disorder, bulimia nervosa, and bipolar depression (in combination with olanzapine).
10mg, 20mg, 40mg, 60mg
Capsules: 10mg, 20mg, 40mg; Tablets: 10mg, 20mg, 60mg; Oral solution: 20mg/5mL; Delayed-release capsules (weekly): 90mg
Category C (risk cannot be ruled out)
Mechanism of Action
Selective serotonin reuptake inhibitor (SSRI) that blocks the serotonin transporter (SERT). Its active metabolite norfluoxetine is also a potent SSRI, contributing to an extremely long effective half-life.
Taper Notes
The 4–6 day parent half-life and 4–16 day norfluoxetine half-life provide intrinsic auto-tapering. Gradual stepwise reductions remain advisable to minimize delayed-onset withdrawal.
Maudsley Deprescribing Guidance
Long active-metabolite half-life buffers each dose reduction. A standard stepwise reduction over 4–8 weeks is usually adequate; abrupt cessation is not recommended despite the kinetic profile.
Tapering Protocol
Evidence-based phased reduction schedule. Always taper under medical supervision.
| Phase | Duration | Notes |
|---|---|---|
| Initial reductions | 4-6 weeks | Reduce by ~25% using available capsule strengths. Norfluoxetine accumulation buffers each step; expect delayed pharmacodynamic effects. |
| Middle reductions | 4-6 weeks | Use 10 mg capsules or oral solution (20 mg/5 mL) for smaller increments. Most patients tolerate this phase without symptomatic withdrawal. |
| Final reductions | 4-8 weeks | Long active-moiety half-life provides intrinsic auto-taper post-discontinuation. Capsule-based stepdowns are typically sufficient without compounding. |
Withdrawal Timeline
3-7 days after dose reduction (delayed by long half-life)
1-2 weeks
2-4 weeks
Uncommon due to long half-life. Some report emotional flatness for 4-6 weeks. Fluoxetine has the mildest withdrawal profile of all SSRIs.
Clinical Pearls
Practical considerations for clinicians supervising Prozac tapers.
- 1The long parent and norfluoxetine half-lives delay rather than eliminate discontinuation symptoms; a measured stepwise taper remains best practice despite the forgiving kinetics.
- 2Oral solution (20 mg/5 mL) is available but typically unnecessary — most patients can be tapered using 10 mg capsules and alternate-day dosing where appropriate.
- 3Fluoxetine cross-taper is a valid Maudsley-endorsed strategy for refractory discontinuation from short-half-life SSRIs/SNRIs; complexity warrants careful patient selection.
- 4Counsel patients that pharmacodynamic effects of dose reductions may be delayed by 1–2 weeks given norfluoxetine's 4–16 day half-life; symptoms are not always temporally linked to the prior reduction.
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- MAOIs — contraindicated (allow 5 weeks washout due to long half-life)
- Thioridazine — contraindicated (QT prolongation)
- Pimozide — contraindicated
Food Interactions
- No significant food effect on absorption
- Grapefruit juice may modestly increase levels
- Avoid alcohol during treatment
Contraindications
- MAOIs within 14 days (5 weeks washout before starting MAOI)
- Thioridazine
- Pimozide
Toxicity
Serotonin syndrome at supratherapeutic doses. QT prolongation rarely reported. Lower toxicity in overdose compared to TCAs.
Pharmacokinetics
ADME Profile
Well absorbed after oral administration. Bioavailability ~72%. Tmax 6–8 hours. Food slightly delays absorption but does not affect overall extent.
~20–45 L/kg
Hepatic via CYP2D6 (primary) and CYP2C9 to the active metabolite norfluoxetine. Fluoxetine is a potent CYP2D6 inhibitor.
Renal (~80%, with ~2.5% as unchanged fluoxetine and ~10% as norfluoxetine). Fecal (~15%).
~94.5%
Apparent oral clearance ~600 mL/min; decreases with chronic dosing due to CYP2D6 inhibition.
Build Prozac taper plans in minutes
TaperMeds turns these protocols into prescriber-ready taper schedules with hyperbolic dose curves, symptom tracking, and patient handouts — for the clinicians supervising the taper.
Try TaperMeds